Tyra Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
RA Capital Management and its affiliates reported a dilution of their beneficial ownership in TYRA Biosciences, now holding 21.2% of common stock.
NASDAQ
SCHEDULE 13D/A: RA Capital Healthcare Fund Significantly Boosts Stake in Tyra Biosciences Through Private and Open Market Purchases
RA Capital Healthcare Fund, L.P. has substantially increased its beneficial ownership in Tyra Biosciences, Inc. to 22.4% through a private stock purchase from Canaan XI L.P. and additional open market acquisitions.
NASDAQ
SCHEDULE 13D/A: RA Capital Management Reaffirms Significant Stake in TYRA Biosciences with Updated SEC Filing
RA Capital Management, L.P. and its affiliates have filed an Amendment No. 4 to their Schedule 13D, confirming their continued beneficial ownership of 20.1% of TYRA Biosciences, Inc.'s common stock.